Patrys Limited

📈 Quarterly Report Patrys Limited has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 September 2024.   Highlights from this period include: 🔹 Specification testing of drug product from GMP production run of PAT-DX1 completed; 🔹 Based on results of specification testing, Patrys to focus internal development efforts on PAT-DX3 and seek partnering or licensing opportunities for PAT-DX1; 🔹 Cash and short‑term investment balance of $1.3 million on 30 September 2024, with an R&D refund of $1.3 million expected in the current quarter Read today’s ASX release here 👉https://lnkd.in/gszQAP5X $PAB #ASX #research #innovation #biotech #cancer #antibodies

📑 ANNUAL REPORT   Patrys Limited has released its Annual Report for the 2023-2024 Financial Year (FY24). Highlights include: ▶  Data from preclinical studies with PAT-DX1 and PAT-DX3 presented at US brain cancer conference ▶  GMP production run of PAT-DX1 completed ▶  Master Cell Bank (MCB) for PAT‑DX3 characterised and validated, and an integration manufacturing run successfully completed ▶  Positive preclinical data demonstrating the use of deoxymabs to arrest NETosis and treat vasculitis, and potentially other autoimmune diseases, presented at international meetings Read the full report here 👉 https://lnkd.in/g92cdejQ   $PAB #ASX #biotech #innovation #pharma #antibodies 

📈 Quarterly Report Patrys Limited has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 June 2024.   Highlights from the period include: 🔹 GMP production run of PAT-DX1 completed during the quarter with specification testing scheduled to be completed by end of July 2024; 🔹 Positive preclinical data demonstrating potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international meetings; 🔹 Cash and short‑term investment balance of $2.2 million on 30 June 2024. Read today’s ASX release here 👉 https://lnkd.in/gfx-xfZx $PAB #ASX #research #innovation #biotech #antibodies

📈 Quarterly Report #Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024.   Key highlights from this period include: 🔹 GMP production run initiated during the quarter, and successfully completed in April with product characterisation and quality verification on track for completion in Q2 CY2024; 🔹 Positive preclinical data highlights the potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international workshop; 🔹 Cash and short-term investment balance of $3 million on 31 March 2024.   Read today’s ASX release here 👉 https://lnkd.in/gpRr9ehc    $PAB #ASX #research #innovation #biotech #cancer #antibodies 

📊 New preclinical data   #Patrys is delighted to announce that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis were presented by Dr Kim O’Sullivan from Monash University during the plenary session at the 21st International Vasculitis Workshop in Barcelona overnight.   Patrys has reported results from non-clinical studies which showed that its deoxymabs suppress the formation of neutrophil extracellular traps (NETs). Emerging research suggests that NETs may play an important role in cancer development, metastasis, and inflammatory processes.   As the formation of NETs is one of the underlying processes in the development of the autoimmune disease ANCA vasculitis, Dr O’Sullivan extended these findings by examining the impact of Patrys’ deoxymabs in an animal model of the disease. Key results from these studies include: 🔹 PAT-DX1 and PAT-DX3 are both able to inhibit the formation of NETs in an animal model of ANCA vasculitis; 🔹 Both deoxymabs reduced the level of inflammation and kidney injury in the animal model of ANCA vasculitis; 🔹 However, neither PAT-DX1 nor PAT-DX3 had any detrimental effect on neutrophils indicating that their administration did not result in any suppression of the immune system.   Patrys Chief Executive Officer and Managing Director, Dr. James Campbell, said:   “ANCA vasculitis is a challenging condition and, while current treatments have transformed it into a relapsing/remitting disease, they are associated with increased drug-related toxicities and organ damage. In view of this, we believe a therapeutic that is able to reduce the inflammation associated with this disease without suppressing the immune system could provide a very attractive therapeutic option for patients. It is particularly exciting to see the potential opportunities to develop or partner our deoxymab technology expand while our GMP manufacturing of PAT-DX1 is underway and nearing completion.”   Read the ASX release 👉 https://lnkd.in/gJ3Jz5JW   $PAB #Patrys #biotech #innovation #deoxymabs #antibodies #vasculitis

🎤 International Conference At #Patrys, we are always excited to learn of the promising potential of our deoxymab technology in new areas of clinical need. This week, we are pleased to announce that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA) vasculitis will be presented at the 21st International Vasculitis Workshop in Barcelona next month. Dr Kim O’Sullivan from Monash University will present on recent preclinical studies that demonstrate the potential to improve treatments for autoimmune diseases like ANCA vasculitis, an inflammatory condition caused by the buildup of of activated neutrophils and neutrophil extracellular traps (NETs) in small blood vessels. Current treatments increase the risk of infections, highlighting the need for safer therapies. Patrys Chief Executive Officer and Managing Director, Dr James Campbell, said: “As GMP manufacturing for PAT-DX1 remains on track to commence in the current quarter, it is exciting to identify additional therapeutic opportunities for our deoxymab platform with promising future partnering and licensing opportunities for Patrys.” Read today’s ASX release 👉 https://lnkd.in/gX2efc9W $PAB #ASX #biotech #innovation #antibodies #vasculitis #conference 

World Cancer Day 🎗   On World Cancer Day, we’re shining a light on global efforts to bridge gaps in cancer knowledge and treatment - all in the name of building a brighter future for patients and their loved ones.   At #Patrys, we are driven by the belief that scientific innovation holds the key to unlocking new and more effective treatment options. Our team is deeply committed to exploring the full potential of our deoxymab technology to deliver meaningful clinical benefits.   $PAB #Patrys #cancer #biotech #innovation #antibodies #clinicaltrial #WorldCancerDay  

📈 Quarterly Report #Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 September 2023.   Highlights from the period include: ✅ GMP manufacturing slot for PAT‑DX1 secured for Q1 CY2024 to provide drug material for first‑in‑human clinical trial expected to commence in 2H CY2024 ✅ GLP toxicology studies for PAT-DX1 have not identified any safety or tolerability issues that are likely to affect the proposed Phase 1 clinical trial of PAT‑DX1 ✅ A Master Cell Bank (MCB) for PAT‑DX3 has been characterised and validated, and an integration manufacturing run has been successfully completed The Company had a cash and short‑term investment balance of $4.5 million on 31 December 2023.   Read today’s ASX release here 👉 https://lnkd.in/g94fd__f    $PAB #ASX #research #innovation #biotech #cancer #antibodies #clinicaltrial

⭐ International Mentoring Day ⭐   At #Patrys, we strongly believe in the transformative power of mentorship in shaping the professional experiences of the next generation of scientists and biotech executives.   Mentoring is a powerful ingredient for growth, innovation, and learning. It is about inspiring and empowering individuals to exceed their own expectations and providing a support system that fosters growth and success.   Today, Patrys CEO and MD, Dr James Campbell, has shared his gratitude for his mentors for their invaluable guidance and support, which have been instrumental in shaping his own journey in the biotechnology industry.   To all our mentors - thank you.   $PAB #innovation #biotech #leadership #mentorship #InternationalMentoringDay

✨ $PAB Update Some positive news as we approach the end of the year… Patrys Limited is pleased to announce that its Contract Manufacturing and Development Oganisation (CDMO) has confirmed that a manufacturing slot for the GMP (Good Manufacturing Practice) production of PAT-DX1 will be available in Q1 CY 2024. Additionally, PAB’s GLP toxicology studies are complete, and no safety or tolerability issues were identified. This news paves the way for Patrys to initiate its its first-in-human clinical trial of PAT-DX1 in the second half of CY 2024. Dr James Campbell said: “I am delighted to confirm that, based on the extensive and rigorous investigations by both our CDMO and external manufacturing consultants, we are now able to recommence our manufacturing program of PAT-DX1 in the upcoming quarter. This manufacturing run is expected to produce the drug material that Patrys will use in the Phase 1 clinical trial of PAT-DX1 that is scheduled for the second half of CY2024. ” Read today’s ASX release 👉 https://lnkd.in/gNEAbRMe $PAB #pharma #biotech #innovation #antibodies #clinicaltrial #cancer